Clinical Trial Update: Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intermittent or continuous panitumumab plus FOLFIRI for left-sided RAS/B-RAF wild-type metastatic colorectal cancer; currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• Panitumumab (panitumumab)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Colorectal Cancer Stage IV | Phase 3 | Status: RECRUITING